Exit
GIC exits Beijing airport to NWS Holdings
GIC Private has exited its 8.84% stake in Beijing Capital International Airport (BCIA)to NWS Holdings, an Chinese infrastructure conglomerate controlled by Hong Kong billionaire Cheng Yu-Tung, for about HK$2.36 billion ($304 million).
Darby exits South Korea’s Leadcorp
Darby Private Equity, a subsidiary of Franklin Templeton Investments, has exited its stake in South Korean consumer finance company Leadcorp through sales on the Kosdaq Market of Korean Exchange. The financial details were not disclosed.
SMBC to buy US rail lessor from Perella Weinberg
Perella Weinberg Partners will exit Chicago-based Flagship Rail Services to Sumitomo Mitsui Banking Corporation (SMBC) in a transaction valued at $1.1 billion.
Moody's acquires Helion-backed Amba Investment Services
Moody’s subsidiary Copal Partners has acquired Helion Ventures-backed Amba Research for an undisclosed sum.
Actis to sell Sterling Hospitals stake back to promoter
Actis will exit a 2006 investment in India’s Sterling Hospitals chain by selling its 82% shareholding back to the founder, Girish Patel. Financial terms of the deal were not disclosed.
Orchid Asia-backed Autohome revises IPO pricing
Autohome, a Chinese online automobile marketplace backed by Orchid Asia, has revised the indicative price range for its US IPO, putting the firm on course to raise up to $143.8 million.
2013: The year in numbers
A snapshot of the year's stand-out fundraising, investment and exit activity
2013 in review: Mixed fortunes
Bifurcation in the fundraising market as LPs play it safe with managers they know; South Korea and India emerge as buyout bright spots; positive signs for IPOs after a difficult 12 months
Japan’s VC-backed Oncolys Pharma raises $64m in Tokyo IPO
Oncolys Pharma, a VC-backed developer of drugs targeting cancer and serious infectious diseases, saw its stock open at JPY3,500 per share - a 34.6% premium on the offering price - on its first day of trading in Tokyo. This followed a JPY6.6 billion ($64.4...
PE-backed China Cinda prices HK IPO at top of range - report
China Cinda Asset Management, a company originally set up to absorb non-performing loans (NPLs) from China’s Big Four state-owned banks, has priced its IPO at the top end of the indicative range and is on course to raise $2.5 billion. It will be Asia’s...
Jafco Asia leads Series B round for US games developer
Japanese venture capital investor Jafco Asia has led a Series B round of funding for US games developer Playnery. The value of the transaction was not disclosed.
Tokio Marine sells Barneys Japan stake to 7 Eleven parent
Tokio Marine Capital Partners has agreed to sell its 49.9% stake in luxury department store operator Barneys Japan to Seven & i Holdings, the parent of 7 Eleven convenience stores and department store operator Sogo & Seibu, for around JPY6 billion ($58...
Anchorage-backed Dick Smith closes flat after $311m IPO
Shares in Australian electronics retailer Dick Smith Holdings, which is backed by Anchorage Capital Partners, gained 3.6% on their trading debut on Wednesday before settling back to A$2.20, the same as the IPO price. The offering earlier raised A$344.5...
Japan's Ride On Express raises $23m in Tokyo IPO
Ride On Express, a Japanese food delivery franchise operator backed by Jafco Ventures, saw its stock open at JPY3105 per share - a 55% premium on the offering price - on its first day of trading. The company earlier raised JPY2.3 billion ($22 million)...
KKR agrees capital injection
Before agreeing to invest $200 million in India's Gland Pharma, KKR looked at a couple of opportunities in the injectable drugs space in the US and another in India over a period of several years. The PE firm has a long-standing interest in the industry...
Asia Awards: Exit of the Year – Matahari Department Store
Two substantial partial exits that can be seen to justify the Indonesia investment thesis for global PE firms were among those nominated for Exit of the Year: TPG Capital and Northstar Group’s agreed sale of more than 30% of Bank Tabungan PensiunanNasional...
Asia Awards: Firm of the Year - KKR
KKR closed its second pan-Asia fund at $6 billion and announced investments of $1.8 billion and distributions of $1.2 billion for the year to September. Capstone, the firm’s operating unit, was a factor in each area
Crescent-owned travel insurer to raise $475m in Australia IPO
Crescent Capital Partners-owned travel insurer Cover-More Group is targeting a A$521.2 million ($475 million) IPO on the Australian Securities Exchange.
Advantage to exit Japan's Nissen for $22.8 million
Advantage Partners, the Japanese mid-market buyout firm, is to exit its stake in catalogue and web-based retailer Nissen Holdings to Seven & i Holdings, the Japanese parent of 7-Eleven and the Ito Yakado supermarket chain, for JPY2.36 billion ($22.8 million).
China to resume IPOs in 2014 – CSRC
The China Security Regulatory Commission (CSRC) plans to re-open the IPO market in January. About 50 firms are expected to pass the regulator’s review and become the first batch to list.
PE firms bid for CVCI-owned BPO firm SourceHOV - report
Apax Partners, The Carlyle Group and Baring Private Equity Asia are said to be among bidders for SourceHOV, a business process outsourcing (BPO) firm jointly owned by Citigroup Venture Capital International (CVCI) and Mumbai-listed HOV Services.
MBK Partners sells Japan-based Invoice to Lone Star
MBK Partners has fully exited Invoice, Japan’s largest telecom bill aggregation service provider, to Lone Star Funds. The sale price was not disclosed but sources close to the deal said the North Asia-focused private equity firm had generated a 2.5x...
Orchid Asia-backed Autohome sets terms for $126m US IPO
Autohome, a Chinese online automobile marketplace in which Orchid Asia is an investor, plans to raise up to $125.9 million through an IPO on the New York Stock Exchange. The private equity firm will not be exiting any shares through the offering.
KKR to invest $200m in Indian drug maker Gland Pharma
KKR has agreed to buy a minority stake in Gland Pharma, an Indian injectable drugs manufacturer, for approximately $200 million. The investment facilitates the exit of Invascent Capital's Evolvence India Life Sciences Fund (EILSF).